Skip to main content

Market Overview

Nomura's Takeaways From Meeting With Gilead Sciences' Management

Share:

Ian Somaiya of Nomura on Friday reiterated a Buy rating on shares of Gilead Sciences, Inc. (NASDAQ: GILD) with a $146 price target following a meeting with the company's management team.

Somaiya notes that additional insight was gained into: 1) HCV pricing and payor negations, 2) potential changes in treatment dynamics, 3) capital allocation, and 4) early stage pipeline including NASH and HBV.

“Overall, we believe barriers to access of HCV drugs will likely decline in 2015, with most plans opting to provide access to both drugs,” Somaiya wrote. “We believe the biggest risk remains annual number of patients the market can treat. While Gilead believes market is capable of treating 250,000 plus patients, reaching that level remains contingent on the degree to which payors open the system.”

The analyst adds that despite the risk, potential upside exists in Europe, where certain markets have established dedicated funds for HCV.

Shares of Gilead Sciences recently traded at $98.62, 1.3 percent.

Latest Ratings for GILD

DateFirmActionFromTo
Feb 2021SVB LeerinkMaintainsOutperform
Feb 2021Credit SuisseMaintainsNeutral
Feb 2021SVB LeerinkMaintainsOutperform

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

 

Related Articles (GILD)

View Comments and Join the Discussion!

Posted-In: HCV Ian Somaiya NASH NomuraAnalyst Color Reiteration Analyst Ratings

Latest Ratings

StockFirmActionPT
SPCEB of A SecuritiesMaintains50.0
TGTBMO CapitalMaintains205.0
AMBACraig-HallumMaintains150.0
TGTJefferiesMaintains188.0
SBNYUBSMaintains275.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com